Back to Search
Start Over
Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.
- Source :
-
Current vascular pharmacology [Curr Vasc Pharmacol] 2012 Jul; Vol. 10 (4), pp. 448-53. - Publication Year :
- 2012
-
Abstract
- The glycoprotein (GP) IIb/IIIa receptor is critical to the process of platelet aggregation and thrombus formation as it serves as the final common pathway for platelet aggregation. For this reason, the development of GP IIb/IIIa inhibitors that block fibrinogen binding to the receptor has become an attractive strategy for antiplatelet therapy with an expected strong and specific effect. Presently, there are three commercially available GP IIb/IIIa inhibitors: abciximab, eptifibatide and tirofiban. All three drugs are commonly administered intravenously, and large-scale clinical trials have demonstrated a clear clinical benefit and good safety profile in patients at high risk, especially those undergoing percutaneous coronary interventions (PCI). Recently, several studies tested the intracoronary (IC) route for GP IIb/IIIa inhibitors in order to verify its safety and its possible superiority as compared to the intravenous (IV) route. The majority of the studies testing the IC route were conducted using abciximab and in patients with STEMI with better results in terms of myocardial reperfusion and infarct size and also promising results in terms of clinical outcome. On the IC administration of eptifibatide and tirofiban only some, even if promising, data are available. Larger and randomized studies are warranted to confirm the superiority of the IC route of administration of the GP IIb/IIIa inhibitors to the IV one in patients with coronary artery disease undergoing PCI.
- Subjects :
- Abciximab
Acute Coronary Syndrome physiopathology
Animals
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Arrhythmias, Cardiac drug therapy
Arrhythmias, Cardiac physiopathology
Arrhythmias, Cardiac surgery
Cardiac Catheterization
Combined Modality Therapy
Heart Failure etiology
Heart Failure prevention & control
Humans
Immunoglobulin Fab Fragments administration & dosage
Immunoglobulin Fab Fragments adverse effects
Immunoglobulin Fab Fragments pharmacology
Immunoglobulin Fab Fragments therapeutic use
Infusions, Parenteral
Platelet Aggregation Inhibitors adverse effects
Platelet Aggregation Inhibitors pharmacology
Platelet Aggregation Inhibitors therapeutic use
Acute Coronary Syndrome drug therapy
Acute Coronary Syndrome surgery
Angioplasty, Balloon, Coronary adverse effects
Platelet Aggregation Inhibitors administration & dosage
Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1875-6212
- Volume :
- 10
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Current vascular pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 22339256
- Full Text :
- https://doi.org/10.2174/157016112800812764